Latest Breaking News On - Company premarket approval - Page 5 : comparemela.com

Sequana Medical announces three month follow-up data from MOJAVE non-randomized cohort

MOJAVE – US Phase 1/2a study of DSR 2.0 for treatment of heart failure

United statesCian crosbieCompany or sequanaCompany premarket approvalCompany us phaseSequana medicalEuronext brusselsChief medical officerChief executive officerData safety monitoring boardSeattle heart failurePremarket approvalNorth american

Sequana Medical announces three month follow-up data from

Sequana Medical announces three month follow-up data from
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

United statesCian crosbieCompany premarket approvalCompany or sequanamedicalCompany us phaseSequana medicalEuronext brusselsChief medical officerChief executive officerData safety monitoring boardSeattle heart failurePremarket approvalNorth american

Sequana Medical NV: Sequana Medical announces three month follow-up data from MOJAVE non-randomized cohort confirming dramatic improvement in diuretic response and virtual elimination of loop diuretics following DSR® therapy

Sequana Medical NV: Sequana Medical announces three month follow-up data from MOJAVE non-randomized cohort confirming dramatic improvement in diuretic response and virtual elimination of loop diuretics following DSR® therapy
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesDennis riedlCian crosbieCompany us phaseCompany premarket approvalCompany or sequanamedicalEuronext brusselsChief medical officerSequana medicalChief executive officerData safety monitoring boardSeattle heart failurePremarket approvalNorth american

Sequana Medical NV: Strong data from DSR® proof-of-concept studies in heart failure accepted for late-breaking presentation at THT 2024

Sequana Medical NV: Strong data from DSR® proof-of-concept studies in heart failure accepted for late-breaking presentation at THT 2024
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesJeffrey testaniCompany premarket approvalCompany or sequanamedicalKey opinion leaderEuronext brusselsDirect sodium removalHeart failureWednesday marchAssociate professorHeart failure researchYale university schoolSeattle heart failureSequana medicalPremarket approvalNorth american

Strong data from DSR® proof-of-concept studies in heart failure accepted for late-breaking presentation at THT 2024

Presentation by Key Opinion Leader Dr. Testani on Wednesday, March 6th 2024Ghent, Belgium – 28 February 2024– Sequana Medical NV (Euronext Brussel.

United statesJeffrey testaniCompany or sequanamedicalCompany premarket approvalKey opinion leaderSequana medicalEuronext brusselsDirect sodium removalHeart failureWednesday marchAssociate professorHeart failure researchYale university schoolSeattle heart failurePremarket approvalNorth american